CIK 0001783183 · Non-accelerated filer<br>Smaller reporting company
Phathom Pharmaceuticals, Inc.
Sign in to watch- Ticker
- PHAT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 824151574
- Phone
- (877) 742-8466
- Business address
- 100 CAMPUS DRIVE,, SUITE 102, FLORHAM PARK, NJ, 07932
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-05-21 | COLA MICHAEL F Director | Grant or award · Stock Option | +10,000 | 10,000 | ||
| 2020-04-01 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Purchase | +117,600 | $24.86 | $2.9M | 3,825,008 |
| 2020-03-31 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Purchase | +30,600 | $24.55 | $751K | 3,707,408 |
| 2020-03-27 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Purchase | +30,000 | $24.60 | $738K | 3,676,808 |
| 2020-03-17 | Stenhouse Mark Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2020-01-05 | Nabulsi Azmi Chief Operating Officer | Sale | −1,854 | $33.77 | $63K | 823,700 |
| 2020-01-04 | Nabulsi Azmi Chief Operating Officer | Sale | −4,932 | $33.02 | $163K | 833,268 |
| 2020-01-04 | Nabulsi Azmi Chief Operating Officer | Sale | −7,614 | $33.93 | $258K | 825,654 |
| 2020-01-04 | Nabulsi Azmi Chief Operating Officer | Sale | −100 | $34.57 | $3K | 825,554 |
| 2019-10-29 | COLA MICHAEL F Director | Purchase | +9,798 | $19.00 | $186K | 9,798 |
| 2019-10-29 | Edwards Jonathan S. Director | Conversion | +991,672 | $15.20 | $15.1M | 991,672 |
| 2019-10-29 | Edwards Jonathan S. Director | Conversion | +23,558 | $15.20 | $358K | 23,558 |
| 2019-10-29 | Edwards Jonathan S. Director | Purchase | +1,028,205 | $19.00 | $19.5M | 2,019,877 |
| 2019-10-29 | Edwards Jonathan S. Director | Purchase | +24,426 | $19.00 | $464K | 47,984 |
| 2019-10-29 | Edwards Jonathan S. Director | Conversion · Convertible Promissory Notes | −0 | 0 | ||
| 2019-10-29 | Edwards Jonathan S. Director | Conversion · Convertible Promissory Notes | −0 | 0 | ||
| 2019-10-29 | Frazier Life Sciences IX, L.P. 10% owner | Conversion | +1,353,640 | $15.20 | $20.6M | 6,231,638 |
| 2019-10-29 | Frazier Life Sciences IX, L.P. 10% owner | Purchase | +1,052,631 | $19.00 | $20.0M | 7,284,269 |
| 2019-10-29 | Frazier Life Sciences IX, L.P. 10% owner | Conversion · Convertible Promissory Notes | −0 | 0 |
Page 19 of 19 · 379 trades